Patents by Inventor Dennis M. Lambert

Dennis M. Lambert has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DNA encoding T-1249 and other viral fusion inhibitor peptides useful for treating aids
    Patent number: 7297784
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: January 24, 2003
    Date of Patent: November 20, 2007
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6656906
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: July 9, 1999
    Date of Patent: December 2, 2003
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Publication number: 20030186874
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Application
    Filed: January 24, 2003
    Publication date: October 2, 2003
    Applicant: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Methods and compositions for inhibition of membrane fusion-associated events including RSV transmission
    Patent number: 6623741
    Abstract: The present invention relates to peptides which exhibit potent anti-retroviral activity. The peptides of the invention are derived from regions of viral fusion proteins referred to as HR1 and HR2. In particular, the invention relates to peptides referred to herein as DP107 and DP178 which comprise amino acid sequences corresponding to sequences found in the HR1 and HR2 regions, respectively of the HIV-1LAI gp41 protein. The invention further relates to “DP107-like” and “DP178-like” peptides that are derived from HR1 and HR2 regions, respectively, of other proteins, including DP107-like and DP178-like peptides derived from the HR1 and HR2 regions of the F1 subunit of the respiratory syncytial virus fusion protein.
    Type: Grant
    Filed: February 29, 2000
    Date of Patent: September 23, 2003
    Assignee: Trimeris, Inc.
    Inventors: James B. Antczak, Mary K. Delmedico, Joel B. Erickson, Dennis M. Lambert, Prakash Sista
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6562787
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: April 13, 2001
    Date of Patent: May 13, 2003
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6348568
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: May 20, 1999
    Date of Patent: February 19, 2002
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert
  • Hybrid polypeptides with enhanced pharmacokinetic properties
    Patent number: 6258782
    Abstract: The present invention relates to enhancer peptide sequences originally derived from various retroviral envelope (gp41) protein sequences that enhance the pharmacokinetic properties of any core polypeptide to which they are linked. The invention is based on the discovery that hybrid polypeptides comprising the enhancer peptide sequences linked to a core polypeptide possess enhanced pharmacokinetic properties such as increased half life. The invention further relates to methods for enhancing the pharmacokinetic properties of any core polypeptide through linkage of the enhancer peptide sequences to the core polypeptide. The core polypeptides to be used in the practice of the invention can include any pharmacologically useful peptide that can be used, for example, as a therapeutic or prophylactic reagent.
    Type: Grant
    Filed: May 20, 1998
    Date of Patent: July 10, 2001
    Assignee: Trimeris, Inc.
    Inventors: Shawn Barney, Kelly I. Guthrie, Gene Merutka, Mohmed K. Anwer, Dennis M. Lambert